| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 1. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | sitagliptin phosphate monohydrate/metformin (Janumet®) |
| Formulation | 50 mg/1,000 mg film-coated tablet |
| Reference number | 630 |
| Indication | As an add on to insulin (i.e., triple combination therapy) for the treatment of patients with type 2 diabetes to improve glycaemic control when diet and exercise plus stable dosage of insulin and metformin alone do not provide adequate glycaemic control |
| Company | Merck Sharp & Dohme Ltd |
| BNF chapter | Endocrine system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 19/01/2010 |